Publication: 3854

Publication: 3854

Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial.

PubMed

DOI

Google Scholar

Citation:: Lancet Haematol vol 10 (10) e825-e837

Year:: 2023
Type:: Manuscript
Funding:: AFT
Endpoint:: Primary
Analysis:: Long-Term-Followup
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:: epub-ppub

Note:

Methodological:: No
Biospecimen:: No
SDC:: No
Book Volume:: 13

Parents:: 3655 3659 3748
Children:: None

Program:: OGC
Primary Committee:: Myeloma
Sec. Committees:

Pharmas:: Janssen Oncology
Grants:

Corr. Author:
Authors:: Peter M Voorhees Douglas W Sborov Jacob Laubach Jonathan L Kaufman Brandi Reeves Cesar Rodriguez Ajai Chari Rebecca Silbermann Luciano J Costa Larry D Anderson Nitya Nathwani Nina Shah Naresh Bumma Yvonne A Efebera Sarah A Holstein Caitlin Costello Andrzej Jakubowiak Tanya M Wildes Robert Z Orlowski Kenneth H Shain Andrew J Cowan Shira Dinner Huiling Pei Annelore Cortoos Sharmila Patel Thomas S Lin Saad Z Usmani Paul G Richardson

Networks:: CA043, CA249, CA824, FL065, LAPS-AL002, LAPS-IL036, LAPS-IL057, LAPS-MA036, LAPS-NC007, LAPS-NY016, LAPS-OH007, LAPS-TX011, LAPS-TX035, LAPS-UT003, NC002, NE003, NEWMEXICO, NY021, OH008, OR013

Study: AFT-29 (GRIFFIN)
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:: 2

Keywords: